Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101) Meeting Abstract
| Authors: | Choueiri, T. K.; Rini, B. I.; Larkin, J. M. G.; Bjarnason, G. A.; Gravis, G.; Gurney, H.; Lee, J. L.; Keizman, D.; Haanen, J. B. A. G.; Tomita, Y.; Uemura, H.; Albiges, L.; Schmidinger, M.; Atkins, M. B.; Mariani, M.; Shnaidman, M.; di Pietro, A.; Motzer, R. J. |
| Abstract Title: | Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101) |
| Meeting Title: | 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 35 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2017 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2017-05-20 |
| Start Page: | 260s |
| Language: | English |
| ACCESSION: | WOS:000411931702094 |
| DOI: | 10.1200/JCO.2017.35.15_suppl.TPS4594 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS4594 -- Source: Wos |
